Lonza Cell & Gene Tech Expo August 2025: Cell Therapy

We operate at the forefront of emerging technologies – spanning cell and gene, microbial and mRNA – to help pioneer our customers’ breakthrough medicines. 

Our offering encompasses development and manufacturing services, products, solutions, testing and automation platforms as well as tools and technologies to enable researchers to develop, de-risk and industrialize their therapy, from basic research to commercialization.

Our solutions encompass:

• Electroporation from small to large scale in research and GMP-manufacturing
• Primary cells and tissues
• Cell culture media and reagents
• Informatics or endotoxin testing
• Closed-cell therapy manufacturing
• CDMO services

Learn about the new 4D-Nucleofector® LV Unit PRO, Lonza's next-generation large-scale electroporation platform, designed to deliver clinically relevant cargos into large volumes of T cells.

Join for a technology introduction and a short dive into selected data sets demonstrating the technologies enhanced performance for CRISPR-based knock-out, knock-in and transposition.